Recombinant peptides as biomarkers for tumor response to molecular targeted therapy

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6421-6429

  Passarella, Ralph J ^a   Li, Zhou ^a   Phillips, John G ^a   Hongmei, Wu ^a   Hallahan, Dennis E ^a,b   Diaz, Roberto ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMYLGLYCYLGLUTAMYLVALYLGLYCYLLEUCYLGLYCINE; PEPTIDE DERIVATIVE; RECOMBINANT HORMONE; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOPANNING; BREAST TUMOR; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; MOLECULAR THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; PEPTIDE LIBRARY; PEPTIDES; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350246115     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0945     Document Type: Article

References (27)

1. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008;7:591-607.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-899
3. Cullinane C, Dorow DS, Kansara M, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65:9633-9636 (Pubitemid 41541437)
4. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98: 267-274 (Pubitemid 44195596)
5. Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, AmarteyJ. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2000;25:100-103
6. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomographyusi ng F-18 fluorodeoxy-glucose. J Clin Oncol 1996;14:1848-1857 (Pubitemid 26185460)
7. Han Z, Fu A, Wang H, et al. Noninvasive assessment of cancer response to therapy. Nat Med 2008;14:343-349 (Pubitemid 351347907)
8. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature byphage display. Nat Med 2002;8:121-127 (Pubitemid 34155122)
9. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage displayp eptide libraries. Nature 1996;380:364-366 (Pubitemid 26097120)
10. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 2004;32: 397-402. (Pubitemid 38813523)
11. Hallahan D, Geng L, Qu S, et al. Integrin-mediated targeting of drug deliveryto irradiated tumor blood vessels. Cancer Cell 2003;3:63-74. (Pubitemid 37443891)
12. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249:386-390 (Pubitemid 20248864)
13. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activityof SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
14. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46:1116-1119 (Pubitemid 36428215)
15. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment bytar geted drug deliveryto tumor vasculature in a mouse model. Science 1998; 279:377-380 (Pubitemid 28063372)
16. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature-a potential therapeutic target. Br J Cancer 1995;72:257-267
17. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin α v β 3 antagonists promote tumor regression byinducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164
18. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999;59:2869-2874 (Pubitemid 29283125)
19. EllerbyHM , Arap W, EllerbyLM, et al. Anticancer activityof targeted pro-apoptotic peptides. Nat Med 1999;5:1032-1038
20. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs 1997;15: 15-28.
21. Hallahan D, Clark ET, Kuchibhotla J, Gewertz BL, Collins T. E-selectin gene induction byio nizing radiation is independent of cytokine induction. Biochem Biophys Res Commun 1995;217: 784-795 (Pubitemid 26019725)
22. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996;56:5150-5155 (Pubitemid 26383029)
23. Hallahan DE, Staba-Hogan MJ, Virudachalam S, KolchinskyA. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res 1998;58:5216-5220
24. Hallahan DE, Virudachalam S. Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat Res 1999;152:6-13. (Pubitemid 29296241)
25. Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm Res 1997;14:2-10. (Pubitemid 27113308)
26. Oyajobi BO, Munoz S, Kakonen R, et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007;6:1701-1708 (Pubitemid 46954046)
27. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-2034 (Pubitemid 32995393)